Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine

[1]  H. Dombret,et al.  BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells , 2015, Oncotarget.

[2]  S. Miyano,et al.  Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. , 2015, Cancer cell.

[3]  M. Maris,et al.  Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study , 2015, British journal of haematology.

[4]  J. Maciejewski,et al.  The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine , 2014, Clinical Cancer Research.

[5]  S. Beausoleil,et al.  Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer , 2013, Clinical Cancer Research.

[6]  J. Carew,et al.  MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy , 2012, Expert opinion on investigational drugs.

[7]  G. Marcucci,et al.  RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. , 2012, Blood.

[8]  E. Lightcap,et al.  Quantitative Proteomic Analysis of Cellular Protein Modulation upon Inhibition of the NEDD8-Activating Enzyme by MLN4924 , 2011, Molecular & Cellular Proteomics.

[9]  Anindya Dutta,et al.  NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.

[10]  Francis J Giles,et al.  Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. , 2010, Blood.

[11]  Torsten Haferlach,et al.  Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. , 2009, Blood.

[12]  J. Esteve,et al.  Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. , 2006, Cancer research.

[13]  N. Iizuka,et al.  Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines , 2005, Proteomics.

[14]  Jim A. Wright,et al.  Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review). , 2003, International journal of oncology.

[15]  E. Lightcap,et al.  A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. , 2000, Proceedings of the National Academy of Sciences of the United States of America.